Author:
Pérez-Callejo D.,González-Rincón J.,Sánchez A.,Provencio M.,Sánchez-Beato M.
Funder
Fundación Investigación Biomédica Puerta de Hierro
ISCIII
FEDER
MINECO
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference123 articles.
1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014
2. Rituximab: pharmacology, clinical indications and health benefits;Méndez,2013
3. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study;Witzens-Harig;Ann Hematol,2014
4. CD20-mediated apoptosis: signalling through lipid rafts;Deans;Immunology,2002
5. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献